The Swedish motor neuron disease quality registry

被引:64
|
作者
Longinetti, Elisa [1 ]
Wallin, Amanda Regodon [1 ]
Samuelsson, Kristin [2 ,3 ]
Press, Rayomand [2 ,3 ]
Zachau, Anne [2 ]
Ronnevi, Lars-Olof [2 ,3 ]
Kierkegaard, Marie [4 ,5 ]
Andersen, Peter M. [6 ]
Hillert, Jan [3 ]
Fang, Fang [1 ]
Ingre, Caroline [2 ,3 ]
机构
[1] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Neurol, R52-R54, S-14186 Stockholm, Sweden
[3] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[4] Karolinska Univ Hosp, Funct Area Occupat Therapy & Physiotherapy, Stockholm, Sweden
[5] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden
[6] Umea Univ, Dept Clin Neurosci, Stockholm, Sweden
关键词
Amyotrophic lateral sclerosis; motor neuron disease; national registry; prospective cohort; epidemiology; AMYOTROPHIC-LATERAL-SCLEROSIS; HOSPITAL ANXIETY; ALS; MORTALITY; TOOL; EPIDEMIOLOGY; PREVALENCE; GUIDELINES; MANAGEMENT; FINLAND;
D O I
10.1080/21678421.2018.1497065
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: We set up the Swedish Motor Neuron Disease (MND) Quality Registry to assure early diagnosis and high-quality health care for all MND patients (mainly amyotrophic lateral sclerosis, ALS), and to create a research base by prospectively following the entire MND population in Sweden. Methods: Since 2015, the MND Quality Registry continuously collects information about a wide range of clinical measures, biological samples, and quality of life outcomes from all MND patients recruited at the time of MND diagnosis in Sweden and followed at each clinic visit approximately every 12 weeks. The Registry includes an Internet based patient own reporting portal that involves patients in the registration of their current symptoms and health status. Results: As of 20th January 2017, the MND Quality Registry included 99% of the MND patients of the Stockholm area (N = 194), consisting mostly of ALS patients (N = 153, 78.9%), followed by patients labeled as MND due to a neurophysiology finding but not fulfilling the criteria for ALS (N = 20, 10.3%), primary lateral sclerosis (N = 13, 6.7%), and progressive spinal muscular atrophy patients (N = 8, 4.1%). A higher proportion of these patients were women (N = 100, 52%), and women and men had a similar age at symptoms onset (59 years). Conclusions: Main strengths of the MND Quality Registry are its clinical, quantitative, qualitative, and prospective nature, providing the researchers potential means of identifying appropriate candidates for clinical trials and other research projects, as well as assuring to the patients an effective and adequate time spent on-site with the healthcare professionals.
引用
收藏
页码:528 / 537
页数:10
相关论文
共 50 条
  • [1] Is the incidence of motor neuron disease higher in French military personnel?
    Vlaar, Tim
    Elbaz, Alexis
    Moisan, Frederic
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2020, 21 (1-2) : 107 - 115
  • [2] The Global Burden of Motor Neuron Disease: An Analysis of the 2019 Global Burden of Disease Study
    Park, Jin
    Kim, Jee-Eun
    Song, Tae-Jin
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [3] A case of motor neuron involvement in Gaucher disease
    Pozzilli, V
    Giona, F.
    Ceccanti, M.
    Cambieri, C.
    Frasca, V
    Onesti, E.
    Libonati, L.
    Di Bari, S.
    Fiorini, I
    Cardarelli, L.
    Santopietro, M.
    Inghilleri, M.
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2019, 21
  • [4] Motor neuron disease mortality rates in New Zealand 1992-2013
    Cao, Maize C.
    Chancellor, Andrew
    Charleston, Alison
    Dragunow, Mike
    Scotter, Emma L.
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2018, 19 (3-4) : 285 - 293
  • [5] Prognostic factors of key outcomes for motor neuron disease in a multiracial Asian population
    Deng, Xiao
    Hao, Ying
    Xiao, Bin
    Tan, Eng-King
    Lo, Yew-Long
    JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 72 : 63 - 67
  • [6] Circulating MicroRNAs as Diagnostic Biomarkers for Motor Neuron Disease
    Wang, Lin
    Zhang, Lijuan
    FRONTIERS IN NEUROSCIENCE, 2020, 14
  • [7] Differential features of motor neuron disease mortality in Spain
    VeigaCabo, J
    AlmazanIsla, J
    SendraGutierrez, JM
    DePedroCuesta, J
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1997, 26 (05) : 1024 - 1032
  • [8] Racial differences in motor neuron disease
    Gundogdu, Betul
    Al-Lahham, Tawfiq
    Kadlubar, Fred
    Spencer, Horace
    Rudnicki, Stacy A.
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2014, 15 (1-2) : 114 - 118
  • [9] Avoiding false positive diagnoses of motor neuron disease: Lessons from the Scottish Motor Neuron Disease Register
    Davenport, RJ
    Swingler, RJ
    Chancellor, AM
    Warlow, CP
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 60 (02) : 147 - 151
  • [10] Nationwide incidence of motor neuron disease using the French health insurance information system database
    Kab, Sofiane
    Moisan, Frederic
    Preux, Pierre-Marie
    Marin, Benoit
    Elbaz, Alexis
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2017, 18 (5-6) : 426 - 433